Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature

Basic and clinical research have shown that the expression of molecules involved in the hepatocellular carcinoma (HCC) cell signaling pathway is related to the sensitivity to molecular-targeted agents. We herein report a case of HCC that was effectively treated with lenvatinib after a poor response...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2021/06/01, Vol.60(11), pp.1709-1715
Main Authors: Shibata, Osamu, Kamimura, Kenya, Ko, Masayoshi, Sakai, Norihiro, Abe, Hiroyuki, Morita, Shinichi, Mizusawa, Takeshi, Sato, Hiroki, Sakamaki, Akira, Terai, Shuji
Format: Article
Language:English
Subjects:
Case Report
Case reports
FGF19
FGFR4
Fibroblast growth factor receptor 4
Fibroblasts
Growth factors
Hepatocellular carcinoma
Internal medicine
lenvatinib
Literature reviews
Liver cancer
molecular targeting agents
Precision medicine
Signal transduction
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Basic and clinical research have shown that the expression of molecules involved in the hepatocellular carcinoma (HCC) cell signaling pathway is related to the sensitivity to molecular-targeted agents. We herein report a case of HCC that was effectively treated with lenvatinib after a poor response to sorafenib. The tumor showed a high expression of fibroblast growth factor receptor 4, which is reportedly related to the sensitivity to lenvatinib in vitro. The information obtained from this case and from our literature review highlights the importance of assessing the expression of the molecules involved in tumors for effective precision medicine.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.6580-20